Vivos Therapeutics, Inc.VVOSNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank17
3Y CAGR-9.4%
5Y CAGR-35.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-9.4%/yr
Annual compound
5Y CAGR
-35.6%/yr
Recent acceleration
Percentile
P17
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2024 | 1.12 | -0.7% |
| 2023 | 1.12 | +121.3% |
| 2022 | 0.51 | -66.2% |
| 2021 | 1.50 | -78.3% |
| 2020 | 6.94 | -31.1% |
| 2019 | 10.08 | -63.0% |
| 2018 | 27.23 | - |